Bringing Context and Clarity to Clinical Trial Research for Clinician and Public Health Audiences: JAMA+ Trials

Alison J. Huang, MD, MAS, MPhil
Derek C. Angus, MD, MPH, FRCP

Disclosures

- Huang: Editorial fees from the JAMA Network; royalty fees from Wolters Kluwer
- Angus: Editorial fees from the JAMA Network; consulting fees from Abionyx, AM Pharma, Bayer, Chugai, Grifols, Partner Therapeutics, Spectral Medical; advisory board fees from Medeloop; voluntarily membership with Abridge Research Collaborative

Why JAMA+ Trials?

….during a time of innovation but also challenge for the clinical trial enterprise, the clinical trialist pipeline, and the reputation and impact of trial evidence

What the clinical trial community prioritizes

The primacy of prospective experimental evidence, versus retrospective observation of outcomes associated with intervention use in routine care

Minimization of bias through procedures such as randomization to address differences in those who do versus do not receive interventions

Pre-specification of objectives and endpoints to promote transparency and responsible interpretation of evidence

Protection of data integrity to ensure that findings from interventional research are accurate, complete, and verifiable

Patient-reported belief in the value of trial evidence


JAMA Network | Open

Original Investigation | Global Health

Global Public Attitudes About Clinical Research and Patient Experiences With Clinical Trials

Annick Anderson, MBA; Deborah Borfitz, BS; Kenneth Getz, MBA

(doi:10.1001/jamanetworkopen.2018.2969)

- More than 84% of patients perceive clinical research to be "very important" to the development of new medicines
- Among those participating in trials, >93% would participate again, and >91% would recommend to family or friends


JAMA Network | Open

Original Investigation | Global Health

Understanding of Clinical Trials Among Patients With Cancer and Their Relatives

Pınar Kubilay Tolunay, MD; Cihan Erol, MD; Seda Kahraman, MD; Seher Yıldız Tacar, MD; Erkan Özcan, MD; Fatma Buğdaycı Başal, MD; Fatih Köse, MD; Mehmet Ali Nahit Şendur, MD; Deniz Tural, MD; İrfan Çiçin, MD; Berna Öksüzoğlu, MD; Saadettin Kılıçkap, MD; Yüksel Ürün, MD

(doi:10.1001/jamanetworkopen.2024.57020)

- Among cancer patients and their relatives surveyed in 2020-2021, >90% believe clinical trials benefit society
- More than 61% believe participation could advance science, and >55% think it would benefit future patients

Public adoption of health interventions without evidence

HEALTH • 6 MIN READ

What to know about a viral menopause trend, according to a doctor

MAY 5, 2026

By Katia Hetter



A viral trend claims that a combination of common o
medications, specifically an allergy drug and an acid
symptoms of perimenopause and menopause.

r/HormoneFreeMenopause • 1y ago
Majestic_Bandicoot92

Pepcid AC the rage away!

Supplements

39F here in perim
back pain after mu
knowledge. I saw
course I ran to try
and I feel pretty o
with this good or

forluvoflemons • 1y ago

Wow. I learn something new everyday. Do you take one everyday? Where can I read more about this?

5 Award Share

Majestic_Bandicoot92 OP • 1y ago

I just started today! It seems safe to take daily but CAN interact with some meds so please check that first. If you google there are a bunch of articles about it for PMDD but it seems like it would apply to hormonal mood swings in peri and menopause as well. Here's one: https://www.newsweek.com/woman-pmdd-antihistamines-pain-changed-life-1993362

5 Award Share

Slow translation of trial evidence into clinician practice

- **Median lag of 16 years (IQR 13–19 years) from pivotal clinical trial publication about acute coronary syndrome** to 90% practice uptake (Am Heart J. 2015;169(2):266-73)
- **Only 3–8.5% of eligible U.S. patients with stroke receiving tPA within 8 years of FDA approval** (Arch Neurol. 2006;63(5):661-4)
- **Surgical practice change after only 3 of 6 large U.K. trials, requiring up to a decade for change** (BMJ Qual Saf. 2023;32(6):341-356)
- **Only modest decline in prescribing of alpha-blockers for hypertension after the ALLHAT trial** (JAMA 2004;291;(1):54-62)

Preferences for evidence vs. influence among clinicians

MEDPAGETODAY

Special Reports > Features

Most Doctors Regularly Engage With Healthcare Influencers on Social Media

— Survey found half reported changing their prescribing choices based on this engagement

by Jennifer Henderson, Enterprise & Investigative Writer, MedPage Today

October 15, 2024 · 3 min read Add MedPage Today on Google





Key study findings:

– 60% of HCPs report changing perceptions of medications based on influencer social media content.

– 50% of HCPs have changed prescriptions based on influencer social media content.

– 69% of HCPs engage with influencer content on social media daily.



Decreased engagement in trial research by academic clinicians

- ↑ Competing clinical productivity pressures
- ↑ Regulatory and operational hurdles in trial research
- ↓ Access to funding or career support for trial research
- ↓ Training and mentorship in conducting clinical trials
- ↑ Expectations about timing and frequency of publication

Limited exposure to trial research among clinician trainees

Medical student research productivity and scholarly impact: A 20-year bibliometric comparison with medical residents

Christian J. Hausner, Michelle Yi, Meet S. Patel, Jack T. Franchino, Charles S. Day

Published: February 23, 2026 • https://doi.org/10.1371/journal.pone.0343160

Study Design	Medical Students
Narrative Reviews	524 (36%)
Case Reports	442 (31%)
Systematic Review	134 (9%)
Observational Study	132 (9%)
Randomized Control Trial	81 (6%)
Meta Analysis	65 (4%)
Multicenter Study	40 (3%)
Clinical Trial	17 (1%)
Total	1443 (100%)

Widening gap between clinician understanding and the complexity of methods and statistics used in trials



METHODS AND ANALYSIS

The Statistical Curriculum Within Randomized Controlled Trials in Critical Illness*

McCullough, James P. A. MMed(ClinEpi)[1,2]; Lipman, Jeffrey MD[2–,6]; Presneill, Jeffrey J. PhD[7,8]

Author Information

Critical Care Medicine 46(12):p 1985-1990, December 2018. | **DOI:** 10.1097/CCM.0000000000003380

ORIGINAL CONTRIBUTION

Medicine Residents' Understanding of the Biostatistics and Results in the Medical Literature

Donna M. Windish, MD, MPH
Stephen J. Huot, MD, PhD
Michael L. Green, MD, MSc

PHYSICIANS MUST KEEP CURRENT

Context Physicians depend on the medical lit
formation. Little is known about residents' abili
how to appropriately interpret research outcor

Objective To evaluate residents' understandi
research results.

JAMA Network | Open

Original Investigation | Statistics and Research Methods

Clinician Conceptualization of the Benefits of Treatments for Individual Patients

Daniel J. Morgan, MD, MS; Lisa Pineles, MA; Jill Owczarzak, PhD; Larry Magder, PhD; Laura Scherer, PhD; Jessica P. Brown, PhD; Chris Pfeiffer, MD, MHS; Chris Terndrup, MD; Luci Leykum, MD, MBA; David Feldstein, MD; Andrew Foy, MD; Deborah Stevens, LCSW-C, MPH; Christina Koch, MD; Max Masnick, PhD; Scott Weisenberg, MD; Deborah Korenstein, MD

Communication gap between clinical trialists and clinical audiences

What trial methodologists communicate fluently

- Data handling & modeling issues
- Complex trial designs & design innovations
- Methodology to promote internal validity
- Differing interpretation of endpoints
- Strategies for bias minimization

VS

What clinical audiences seek to understand

- Does this apply to my patient?
- How certain is this finding?
- Should this change my practice?
- What are the real-world trade-offs of use?
- Why did this take so long and cost so much?

Concern about the value proposition of clinical trials

JAMA Summit Report | Clinical Trials

The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided

This paper summarizes recommendations for improving the integration of clinical trials and health care delivery as discussed and at JAMA Summit.

Download the JAMA Summit Report



- Insufficient high-quality, clinically relevant RCTs
- RCTs producing answers that are too narrow
- RCTs producing answers that are too broad
- RCTs that are too challenging or resource-intensive to conduct

See: https://jamanetwork.com/channels/trials/pages/integrating-clinical-trials-and-practice

Greater interest in statistical modeling of observational data vs. experimental trial research



JAMA+ Trials

A new online platform (https://jamanetwork.com/channels/trials) to augment and amplify the combined clinical trials content of the JAMA Network

A forum for highlighting the implications and innovations of trial research across diverse clinical fields to advance medicine and public health

An opportunity to build bridges between the clinical trial community and the broader audiences of the JAMA Network

JAMA+ channels

JAMA+ AI

Editor: Roy Perlis, MD, MSc

JAMA+ AI highlights the role of artificial intelligence and digital medicine in health care, drawing on original research, editorials, and medical news from across the JAMA Network.

JAMA+ Women's Health

Editor: Linda Brubaker, MD, MS

JAMA+ Women's Health is a curated source of trusted clinical information from the JAMA Network that advances health care for women worldwide.

JAMA+ Trials

Editor: Alison Huang, MD, MAS

JAMA+ Trials highlights the implications and innovations of clinical trial research from across the JAMA Network to advance evidence-based medicine and public health.

The JAMA Network:

~60 clinical trial research publications/month across 13 journals

Our Journals

JAMA

Explore the latest in medicine from around the world, including critical care, oncology, AI, cardiology, women's health, infectious disease, and more.

JAMA Network Open

JAMA Cardiology

JAMA Dermatology

JAMA Health Forum

JAMA Internal Medicine

JAMA Neurology

JAMA Oncology

JAMA Ophthalmology

JAMA Otolaryngology–Head & Neck Surgery

JAMA Pediatrics

JAMA Psychiatry

JAMA Surgery

Clinical trials published across selected JAMA Network journals from 2021 to 2025



Top downloaded and cited JAMA research of 2025

Top downloaded articles	Online date
Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Controlled Trial	9-Nov-25
Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial	29-Oct-25
Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score	29-Oct-25
Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial	
Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial	

Top cited articles	Online date
Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial	28-Jul-25
Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer The REAL Randomized Clinical Trial	8-Oct-25
Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke The POST-TNK Randomized Clinical Trial	18-Feb-25
Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The Post-UK Randomized Clinical Trial	13-Jan-25
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial	15-April-25

The JAMA Network audience:

Experienced clinician trialists

Experienced trial statisticians

Early or aspiring clinical trialists

Scientific educators

Clinicians, health system leaders, public health advocates with no prior significant experience with or immediate plans to conduct clinical trials

What do broader medical and public health audiences want to know about clinical trials?



Goals of JAMA+ Trials

- Advance **clinician and public understanding of the implications and innovations of trial research** across the JAMA Network



- **Highlight how trials converge and diverge across clinical disciplines and interventions and populations** served by all the JAMA Network journals

- Catalyze **conversations about innovations in the design or methods of trials** that increase their impact, efficiency, and representativeness

- Promote **honest dialogue about challenges and controversies** in clinical trials to enhance professional and public trust in the trial enterprise

Differences from other clinical trial education resources







CTMC clinical trials methodology course

Curated access to clinical trial publications since 2022



Concise summarization of clinical trial research for clinician audiences

JAMA Research Summary

Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures

The study compared whether applying tobramycin and vancomycin powders topically to a surgical incision during closure of definitive fixation was more effective than applying vancomycin powder alone in reducing deep surgical site infection in periarticular tibial fractures.

Why Does This Clinical Trial Matter?

Periarticular tibial fractures are typically treated with plate and screw fixation , and infections are common and serious complications. Understanding how best to reduce infection rates could improve outcomes for patients with these injuries.

Who Was Involved?

- **Participants Analyzed:** 1528 Randomized adults were included in the primary analysis
- **Type:** Adults (18-80 years)
- **Age (mean):** 47.0 years
- **Sex:** 39.5% female, 60.5% male
- **Locations:** 39 US trauma centers
- **Eligibility Criteria:** Tibial plateau or tibial pilon fracture treated with plate and screw fixation at high risk of infection

How Was the Trial Done?

- **Trial Type:** Open-label, assessor-masked, randomized clinical trial
- **Randomization Details:** Individuals randomized 1:1 to treatment groups

Interventions

- Either 1.2 g of tobramycin plus 1.0 g of vancomycin powder or 1.0 g of vancomycin powder
- **Intervention Details:** Powders applied to the wound bed during surgical closure
- **Mode of Delivery:** Topical application at surgery
- **Timing of Outcome Assessment:** Outcomes measured 182 days after definitive plate and screw fixation

What Was Found?

Primary Outcome

- Deep surgical site infections requiring surgery occurred in 51 patients (7.4%) of 753 in the tobramycin plus vancomycin group and 47 patients (6.6%) of 775 in the vancomycin-only group at 182 days.
- No statistically significant difference was found.

Adverse Events

- Infection rates with gram-negative, gram-positive, polymicrobial, or negative culture pathogens were similar between groups.
- Skin infections treated only with antibiotics were also similar.
- Kidney insufficiency occurred in 0.1% of participants in each group.

Deep surgical site infection within 182 days

Combined treatment
51 of 753 Patients (probability, 7.4%)

Single treatment
47 of 775 Patients (probability, 6.6%)

What This Means

The results suggest that adding tobramycin powder to vancomycin powder during surgery for high-risk periarticular tibial fractures does not offer extra protection against deep surgical site infection compared with vancomycin alone. Both regimens had similar safety profiles.

Limitations and Knowledge Gaps

The study only included patients at high risk of infection, so results may not apply to others. Some infections may present after 182 days and were not captured. The unmasked design may introduce bias. Further research is needed in broader fracture populations.

Existing JAMA trials-related resources & collections

CONSORT & SPIRIT guidelines updates

Trial Protocol & Reporting Guidelines

SPECIAL COMMUNICATION

CONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials

Sally Hopewell, DPhil, An-Wen Chan, MD, DPhil, et al.

JAMA | April 14, 2025

SPECIAL COMMUNICATION

SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomized Trials

An-Wen Chan, MD, DPhil, Isabelle Boutron, MD, PhD, et al.

JAMA | April 28, 2025

Guidance on statistics & methods relevant to trials

JAMA Guide to Statistics and Methods

Platform Clinical Trials for the Efficient Evaluation of Multiple Treatments

JAMA | Review | February 17, 2025 |

This Guide to Statistics and Methods provides an overview of platform trials, describes the characteristics that make them more efficient for evidence generation, and discusses their limitations.

Amyotrophic Lateral Sclerosis | Neurology | Neuromuscular Diseases | Research, Methods, Statistics | Guide to Statistics and Methods

Full Text | PDF | CME & MOC

Factorial Clinical Trial Designs

JAMA | Review | January 15, 2025 |

This JAMA Guide to Statistics and Methods article discusses clinical trials using factorial designs in which participants receive several randomized interventions simultaneously to allow efficient evaluation of multiple therapies and their combinations.

Acid Base, Electrolytes, Fluids | Research, Methods, Statistics | Guide to Statistics and Methods | Clinical Pharmacy and Pharmacology | Drug Development

Full Text | PDF | CME & MOC

Win Ratio Method for Hierarchical Composite Outcomes in Randomized Clinical Trials

JAMA | Review | January 28, 2026 |

This Guide to Statistics and Methods provides an overview of the win ratio method for analyzing composite end points in randomized clinical trials, including its benefits and limitations.

Research, Methods, Statistics | Health Care Quality | Guide to Statistics and Methods

Full Text | PDF | CME & MOC

Meta-research and commentary about clinical trials

Research, Reviews, and Commentary

In case you missed it, explore recent content about clinical trials from across the JAMA Network.

Research

Physical Accessibility of Medicines in Countries Hosting Trials for FDA Approvals

Chris J. Lee, BS; Cary P. Gross, MD; Jennifer E. Miller, PHD

JAMA Internal Medicine | *Original Investigation* | *November 17, 2025*

Barriers and Facilitators of Platform Trials

Stuart McLennan, PhD; Alexandra Griessbach, PhD; Sharon Love, PhD; et al

JAMA Network Open | *Original Investigation* | *April 2, 2026*

Commentary

Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards

Scott R. Evans, PhD, MS; Thomas R. Fleming, PhD; Holly Janes, PhD; et al

JAMA | *Perspective* | *March 23, 2026*

FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials

Andrew Gelman, PhD; Erik van Zwet, PhD; Witold Więcek, PhD

JAMA | *Perspective* | *March 23, 2026*

EXPAND

Editors' Choice: Clinical Trials of the Year

JAMA+ Trials

Home | Trials Resources | Search & Browse

Editor's Choice: Clinical Trials of the Year

Trials selected by JAMA Network journal editors for their unique interest, impact, or innovation.

Kirsten Bibbins-Domingo, PhD, MD, MAS
Editor in Chief, *JAMA*

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2

Eli N. Perencevich, MD, MS
Editor in Chief, *JAMA Network Open*

Protection Against Persistent HPV-16/18 Infection After Different Number of Doses of Quadrivalent Vaccine in Girls and Young

Barbara Casadei, MD, DPhil
Editor, *JAMA Cardiology*

High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: A Prespecified Secondary Analysis of the

Editor's Choice: Clinical Trial of the Year

Trials selected by JAMA Network journal editors for their unique interest, impact, or innovation.

***JAMA*, Kirsten Bibbins-Domingo, Editor in Chief**

Do you agree that this "wildly ambitious" trial of personalized sepsis management across 19 countries was worthy of being singled out by our *JAMA* Editor in Chief?

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial

More Clinical Trials of the Year >

Editor's Choice: Clinical Trial of the Year

Trials selected by JAMA Network journal editors for their unique interest, impact, or innovation.

***JAMA Pediatrics*, Dimitri A. Christakis, MD, MPH, Editor**

Find out why our *JAMA Pediatrics* Editor selected this trial that dared to re-evaluate a canoncial program involving intensive home nurse visits to reduce child abuse and neglect.

Intensive Nurse Home Visiting and Early Childhood Outcomes: A Randomized Clinical Trial

Read the Editor's Note >

Editor's Choice: Clinical Trial of the Year

Trials selected by JAMA Network journal editors for their unique interest, impact, or innovation.

***JAMA Otolaryngology–Head & Neck Surgery*, Jay F. Piccirillo, Editor**

Find out why our *JAMA Otolaryngology HNS* Editor admires this "elegant" trial that separates the contribution of "who fits the hearing aid" from "which hearing aid is used."

Hearing Aid Service Models, Technology, and Patient Outcomes: A Randomized Clinical Trial

Read the Editor's Note >

More Clinical Trials of the Year >

Editor’s Choice for Clinical Trial of 2025 for JAMA

I'm Dr Kirsten Bibbins-Domingo, I'm the Editor in Chief of JAMA and the JAMA Network. And today I'm telling you about one of my favorite trials of 2025. This is the ANDROMEDA-SHOCK-2 randomized clinical trial that looked at a personalized approach to resuscitation in early septic shock, focusing on capillary refill time.

Here are the reasons that I really like this trial. One, this study is looking at a personalized approach to delivering a health care intervention. And this is all the rage right now in the studies that we are seeing, we know that a one-size-fits-all doesn't really work for patients….



Theme of the Month: Virtual and Remotely Conducted Trials

Theme of the Month



Virtual and Remotely Conducted Trials: Connection Without Contact

Have remote research platforms succeeded in democratizing access to clinical trials, or are they creating new forms of trial exclusion?

Alison J. Huang, MD, MAS; Gregory M. Marcus, MD, MAS; An-Wen Chan, MD, DPhil

Read the Editorial in JAMA >

"Virtual and remote trials represent a critical shift in how interventional research is conducted, with participants engaging in clinical trials from where they live or work rather than making repeated visits to brick-and-mortar research sites. Leveraging the increasingly widespread use of smartphones, personal computers, and the internet… decentralized trials relying on digital tools to engage participants remotely have proliferated rapidly...."

Theme of the Month: Virtual and Remotely Conducted Trials

Featured Trials

ORIGINAL INVESTIGATION

Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial

JAMA

ORIGINAL INVESTIGATION

Emollients to Prevent Pediatric Eczema: A Randomized Clinical Trial

JAMA Dermatology

ORIGINAL INVESTIGATION

Remote Access to Urinary Incontinence Treatments for Women Veterans: The PRACTICAL Randomized Clinical Trial

JAMA Network Open

ORIGINAL INVESTIGATION

Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain: A Randomized Clinical Trial

JAMA

View More Trials in This Theme >

Theme of the Month: Trials That Inform Health Policy

Theme of the Month

Trials That Inform Health Policy: A Bridge Too Far?

Is there an inherent mismatch between the broad scope and rapid speed of most policy decisions and the deliberate specificity and methodical pace of traditional trial research?

Alison J. Huang, MD, MAS; Sandro Galea, MD, DrPH

Read the Editorial in JAMA >

"Seldom are health policy decisions guided solely—or even primarily—by evidence from clinical trials. Policymakers often adopt or fund interventions for broad populations based on incomplete information, and under time pressure, budgetary constraints, and competing political demands. Clinical trialists, in contrast, may focus on generating internally valid answers to highly specific questions under carefully controlled conditions, a process that can take years of planning, data collection, and analysis....."

Theme of the Month: Trials That Inform Health Policy

Featured Trials in This Theme

ORIGINAL INVESTIGATION

Nutrition Info and Other Front-of-Package Labels and Simulated Food and Beverage Purchases: A Randomized Clinical Trial

JAMA Network Open

ORIGINAL INVESTIGATION

Integrating Tobacco Treatment Into Lung Cancer Screening: The Screen Assist Factorial Randomized Clinical Trial

JAMA Internal Medicine

ORIGINAL INVESTIGATION

Economic Evaluation of Tobacco Treatments From the Screen ASSIST Lung Cancer Screening Trial

JAMA Network Open

ORIGINAL INVESTIGATION

DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial

JAMA

View More Trials in This Theme >

Potential future trial themes of the month



AI-Augmented Clinical Trials

Trials in Resource-limited Settings

Community Engagement in Trials

Practice-Embedded Trials

Informed Consent in Trials

- Deescalation & Discontinuation Trials
- Trials Terminated Early
- Pilot and Feasibility Trials
- Pragmatic Trial Design
- Long-Term Trial Extension Studies

Thank you - discussion and questions welcome!

Scan to sign up for email alerts, or visit:
https://jamanetwork.com/channels/jamaplus/pages/trials

Email: Alison.Huang@ucsf.edu, Alison.Huang@jamanetwork.org
Social: https://www.linkedin.com/in/alison-huang-76863726/